Mayo Clinic proceedings
-
Mayo Clinic proceedings · Jun 2022
Meta AnalysisNewer P2Y12 Inhibitors vs Clopidogrel in Acute Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock: A Systematic Review and Meta-analysis.
To evaluate the outcomes, safety, and efficacy of dual antiplatelet therapy (DAPT) with newer P2Y12 inhibitors compared with clopidogrel in patients with acute myocardial infarction (AMI) complicated by cardiac arrest (CA) or cardiogenic shock (CS). ⋯ In patients with AMI-CA/CS receiving DAPT, compared with clopidogrel, newer P2Y12 inhibitors were associated with lower rates of early and 1-year mortality. Data on major bleeding and stent thrombosis were inconclusive.
-
Mayo Clinic proceedings · Feb 2022
Retraction Of Publication Meta AnalysisTEMPORARY REMOVAL: Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
To maintain living, interactive evidence (LIvE) on the benefits and harms of different treatment options in adults with cancer-associated thrombosis (CAT). ⋯ Open Science Framework (https://osf.io/dth86).
-
Mayo Clinic proceedings · Sep 2021
Meta AnalysisThe Effectiveness and Safety of Platelet-Rich Plasma for Chronic Wounds: A Systematic Review and Meta-analysis.
To evaluate the effectiveness and adverse events of autologous platelet-rich plasma (PRP) in individuals with lower-extremity diabetic ulcers, lower-extremity venous ulcers, and pressure ulcers. ⋯ Autologous PRP may increase complete wound closure, shorten healing time, and reduce wound size in individuals with lower-extremity diabetic ulcers. The evidence is insufficient to estimate an effect on wound healing in individuals with lower-extremity venous ulcers or pressure ulcers.
-
Mayo Clinic proceedings · Jul 2021
Meta AnalysisJanus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis.
To assess the risk of venous thromboembolism (VTE) in patients treated with Janus kinase (JAK) inhibitors in clinical trials. ⋯ We found insufficient evidence to support an increased risk of JAK inhibitor-associated VTE based on currently available data.
-
Mayo Clinic proceedings · May 2021
Letter Meta AnalysisOmega-3 Benefits Remain Strong Post-STRENGTH.